Question

In the phase 3 COMET trials, which outcome best reflects the clinical benefit of acoltremon in patients with DED?

No difference from vehicle in Schirmer scores through 90 days

Significant tear production increases within 14 days, sustained through 90 days

Improvements in ocular redness, with no impact on patient-reported outcomes

Rapid tear production improvement requiring concurrent corticosteroid therapy

Answer 1

Significant tear production increases within 14 days, sustained through 90 days.

This outcome shows a rapid, objective and durable improvement in tear production, which best reflects clinical benefit in DED.